Hepatitis C virus (HCV) is a major risk factor for human hepatocellular carcinoma (HCC) but the mechanisms underlying HCV-induced carcinogenesis are still poorly understood. We have hypothesized that viral variants, selected during long-term infection, might contribute to cellular transformation. To address this issue, we have investigated the effect of natural HCV core variants isolated from liver tumors (T), or their non-tumor (NT) counterparts, on the tumor growth factor-b (TGF-b) pathway, a major regulator of cellular proliferation, differentiation and apoptosis. We have found a significant reduction in TGF-b reporter gene activity with the expression of core sequences isolated from liver tumors. In contrast, moderate or no effects were observed with non-tumor mutants or a core reference sequence. The molecular mechanisms have been characterized and involved the inhibition, by tumor-derived cores, of the DNA-binding activity of the Smad3/4 transcription factors complex. This inhibition occurs through a direct interaction between the central domain (amino acids 59-126) of tumor-derived core and the MH1 DNA-binding domain of Smad3, thus preventing its binding to DNA. We have therefore identified a new cell-signaling pathway targeted by HCV core and inhibited by tumor-derived core sequences. These results suggest that during chronic infection, there is selection of viral variants that may promote cell transformation by providing, to clonally expanding cells, resistance to TGF-b antiproliferative effects. Oncogene (2005) 24, 6119-6132.
Introduction
In approximately 80% of patients, hepatitis C virus (HCV) infection leads to chronic infection and is associated with a high risk of liver cirrhosis and hepatocellular carcinoma (HCC) (Shiffman, 2004) . It is currently the principal reason for liver transplantation worldwide. HCV belongs to the Hepacivirus genus within the Flaviviridae family. HCV is an enveloped virus with a single-stranded, positive-sense RNA genome of 9.6 kb. This RNA encodes a single polyprotein of 3011 amino acids (aa) that is co-and posttranslationally cleaved by cellular and viral proteases to release 10 proteins (Major and Feinstone, 1997) . The structural proteins consist of two envelope glycoproteins (E1 and E2) and a nucleocapsid protein, or the core protein. Viral replication requires several non-structural proteins (NS) and the viral RNA-dependent RNA polymerase. HCV exists as quasi-species in patient sera or tissues and its genetic variability has been well characterized, especially for the hypervariable region 1 (HVR1) of E2 and NS5A (Polyak et al., 1998) . This genetic variability may have several important effects with respect to the promotion of viral persistence and pathogenesis, and it may generate viral escape mutants from the immune system and resistance to interferon therapy. Indeed, a switch from acute to chronic infection has been associated with a wider variety of quasi-species (Thimme et al., 2002) . Another property of these quasispecies is their compartmentalization into different cell types such as the liver or peripheral blood mononuclear cells (PBMC) (Lerat et al., 1998) . Moreover, in the liver, different viral variants have been isolated according to different tissue sub-localization, in tumor (T) and non-tumor (NT) regions, suggesting that they may contribute to HCV-induced carcinogenesis (Ruster et al., 2001; Alam et al., 2002) . Insufficient appropriate in vitro or in vivo experimental models are available to explore the biological properties of these quasi-species, and in particular to study their direct impact on liver carcinogenesis (Bartenschlager, 2004) .
The core nucleocapsid of HCV is located at the very N-terminus end of the polyprotein; the immature form has 191 aa (p24) and contains the endoplasmic reticulum (ER) signal peptide of the adjoining E1 protein. The mature form is believed to be cleaved initially by a signal peptidase at aa 191 and then by a signal peptide peptidase (SPP) between aa 179 and 180 within the ER membrane (p21) (McLauchlan et al., 2002) . HCV core has been shown to be associated with lipid droplets, which are produced by the ER (Barba et al., 1997) . HCV core has also been observed widely in the cytoplasm, being either diffused or in dot-like structures, or associated with ER or mitochondria (Schwer et al., 2004) . In some in vitro models, full-length (Yasui et al., 1998) or truncated forms (at aa 126) of core have been observed in the nucleus. Besides its role in viral assembly, the core protein has been reported to interact with various cellular proteins (Tellinghuisen and Rice, 2002) , including ApoAII (Sabile et al., 1999) , members of the TNF receptor family, p53 and Stat3, and to modulate the control of cell proliferation and apoptosis (Lai and Ware, 1999) . Furthermore, transgenic mice expressing core or HCV full-length polyprotein develop liver steatosis and later HCC (Moriya et al., 1998; Lerat et al., 2002) . These observations have led to the hypothesis that HCV core may be implicated in liver carcinogenesis, both by triggering chronic inflammation and by directly modulating cell signaling.
Of the major cell signaling pathways controlling cell proliferation, differentiation and apoptosis, transforming growth factor-b (TGF-b) plays a pivotal role. It also controls repair processes and is involved in fibrogenesis through its action on the extracellular matrix. In HCVinfected patients, high levels of TGF-b are found, suggesting that this pathway is activated during chronic infection, which correlates with the fibrosis observed (Nelson et al., 1997; Marcellin et al., 2002; Neuman et al., 2002) . The TGF-b cell signaling pathway displays a tumor suppressor activity through cell cycle arrest in G1 phase. Although the mechanism by which TGF-b causes cell cycle arrest is not as yet fully understood, several studies have shown an up-regulation of the cyclin-dependent kinase inhibitors p21, p27 and p15. The TGF-b pathway involves several effectors such as R-Smads (Smad2, Smad3) that are phosphorylated upon binding of the TGF-b with its cell surface receptor (TGF-R) to form a heterotrimer with Smad4. This complex of two phosphorylated R-Smads and one molecule of Smad4 then translocates to the nucleus where it activates TGF-b responsive genes (Shi and Massague, 2003) . Smad molecules share a common structure consisting of two principal domains, an aminoterminal DNA-binding domain (MH1 domain) and a versatile protein-protein interacting module (MH2 domain) connected through a linker region. Mutations in the TGF-R or R-Smads are associated with carcinoma or lymphoproliferative disorders, indicating a major role of this pathway in the control of cellular proliferation (Massague et al., 2000) . Furthermore, with respect to oncogenic viruses such as EBV, HTLV-1, HPV and adenovirus, several viral proteins have been shown to impair the TGF-b pathway through various direct or indirect mechanisms (Nishihara et al., 1999; Arnulf et al., 2002; Fukuda et al., 2002; Lee et al., 2002b) . This suggests that inhibition of this pathway may participate in the process of several viral-induced neoplasia.
Previous studies have shown that HCV variants are selected during long-term chronic infection. A few studies have yielded data consistent with an impact of HCV variants on some HCV protein biological functions (Laporte et al., 2003; Pellerin et al., 2004) . Given the above-mentioned effects of core and the key role of the TGF-b signaling pathway in cellular transformation, we have tested the hypothesis that the TGF-b pathway could be a target for core variants.
Natural core variants were isolated from liver tumors or their non-tumor counterparts. Tumor-derived core variants have accumulated specific mutations which were not found in non-tumor or serum isolates. These variants exhibited new phenotypic properties and inhibited the TGF-b cell signaling pathway. By investigating the molecular mechanisms underlying this impairment, we have demonstrated an inhibition of the DNA-binding activity of the Smad3/4 complex through a direct interaction between tumor-derived core and Smad3. Mapping of the core and Smad3 domains involved has shown that the central domain of core (aa 59-126) and the DNA-binding domain (MH1) of Smad3 were crucial for this interaction. We have thus identified a new cell-signaling pathway modulated by HCV core protein, dependent on core tumor-derived sequences, which might contribute to HCV pathogenesis and HCVassociated carcinogenesis.
Results

HCV core sequences isolated from liver tumor exhibit a limited number of non-synonymous mutations
In order to investigate HCV core variability in HCC, sequences were isolated from tumor T and non-tumor NT liver tissues of four independent patients with HCVrelated HCC: A and B, previously described in Delhem et al. (2001) , and patients P and T (Table 1) . These patients were infected with HCV 1b genotype and their respective T and NT sequences were compared to a core reference sequence of the same genotype (C1b). This comparison has shown a limited number of nonsynonymous mutations: ANT, 3; AT, 4; BNT, 5; BT, 7; PNT, 2; PT, 1; TNT, 3; and TT, 4. We have classified them into three separate groups based on different criteria. The first group corresponds to mutations that have been called polymorphism, meaning amino-acid substitutions that are very often present in data banks (HCVDB; http://hepatitis.ibcp.fr) and which were found in 50% of our isolates (i.e. aa 52 A or T, aa 70 R or Q and aa 91 L or M). The second group includes substitutions that were only found in the different patients studied (patient A: aa 82, 110 and 130; patient B: aa 75, 147 and 158; patient T: aa 187) and the third group contains substitutions unique to tumor tissue (patient AT: aa 7; patient BT: aa 118 and 189; patient TT: aa 124). When compared with core sequences from 200 sera, substitutions from the third group were not found, suggesting that they were specific to tumor tissues. Tumor sequences did not exhibit any hot-spot mutations, but displayed amino-acid substitutions in the central (aa 59-126) and C-terminal (aa 127-191) domains. Thus, even though core is a structural protein, highly conserved within the different genotypes, nonsynonymous mutations are selected during chronic infection and some of them are specific to tumor tissues.
HCV cores isolated from liver tumor inhibit the TGF-b pathway
To analyse the effect of HCV core mutants on the TGFb cell-signaling pathway, the Hep-G2 hepatoma cell line was used to cotransfect the different core T or NT from patients A, B, P and T with a TGF-b-responsive luciferase reporter gene. This reporter construct contains 12 repeats of the CAGA sequence recognized by the TGF-b-activated transcription factor Smad3/4 complex. Fold stimulation after TGF-b treatment was calculated after normalization with a b-gal reporter assay. As shown in Figure 1a , various degrees of inhibition were observed with the different core mutants when compared with a core reference sequence (C1b) or with no addition of core (empty vector ¼ CAGA control). Within the four couples of T and NT, the inhibitory effects were more pronounced with all T core isolates with significant P values o0.05. Moderate to few effects were observed with the corresponding NT core mutants. As a positive control of TGF-b pathway inhibition, the Tax oncoprotein from HTLV-1 was used (Arnulf et al., 2002) . With Tax, 85% inhibition was observed, whereas 38, 59, 50 and 47% inhibition were observed, respectively, with AT, BT, PT and TT. Among the four T core isolates, BT was chosen for further studies, for its stronger inhibitory effect in the TGF-b reporter assay. The specificity of this inhibition was addressed using increasing amounts of BT (1, 2 or For each patients A, B, P and T, T and NT sequences have been isolated, cloned and their amino-acid (aa) sequences have been compared to a reference core sequence C1b (derived from pCV-J4L6 genotype 1b). Amino-acid differences are indicated by their single-letter code, identical aa are represented as dots. In the C1b reference sequence black letter correspond to polymorphism, black-bold letters correspond to aa changed in both T and NT within the same patients and black-bold-underlined letters to aa specific to T sequences HCV tumor-derived core inhibit TGF-b signaling N Pavio et al 5 mg), and indeed, a dose-dependent effect was observed ( Figure 1b) . In contrast, with BNT or C1b no dosedependent effects were observed (Figure 1b) . To correlate the inhibition observed with BT protein expression, we have used a plasmid carrying a stop codon at aa 7 in the BT core-coding region. Using this control, no inhibitory effect was observed on the TGF-b reporter assay, confirming that the BT protein was clearly responsible for this effect (Figure 1b) . In all experiments, treatment with TGF-b had no effect on the expression level of the various core isolates transfected (data not shown). These results therefore demonstrate that core proteins selected from tumor tissue exhibited a new phenotypic property and were able to block the TGF-b signaling pathway.
HCV core inhibition of TGF-b signaling is rescued by Smad3 but not Smad2 or Smad4
To investigate the molecular mechanisms underlying inhibition of the TGF-b pathway by HCV core mutant BT, over-expression of the transcription factors activated after the binding of TGF-b to its receptor was carried using transient cotransfection of Smad2, -3 or -4 in the previously described reporter assay system. Induction ratios with and without different Smad2, -3 or -4 were calculated after TGF-b stimulation in the presence of BT, C1b, BNT, Tax or empty vector. In the presence of BT, only the overexpression of Smad3 could rescue an induction ratio of 1 (Figure 2a ), while neither Smad2 nor Smad4 could do so (Figure 2b ). When Smad3 concentration was reduced, partial rescue was observed, suggesting that core/Smad3 stoichiometric ratio is important (data not shown). Overexpression of Smad2, -3 or -4 with C1b or BNT did not show any effect (Figure 2a and b) . These results indicate that the step blocked by BT involved the Smad3 transcription factor.
HCV core does not affect the nuclear translocation of the Smad3/4 complex To further characterize changes to the fate of Smad3 in the presence of BT, shuttling of the Smad3/4 complex between the cytoplasm and the nucleus was investigated. Nuclear and cytoplasmic extracts were performed in Hep-G2 cells transfected with different HCV core sequences, including BT, BNT, C1b or empty vector. The shuttling of endogenous Smad3 and Smad4 after TGF-b stimulation was followed by immunoblotting. Under these four experimental conditions, similar levels of Smad3 and -4 were observed in the nucleus following TGF-b induction (Figure 3a) . The three different core sequences BT, BNT and C1b, did not affect levels of Smad3 and -4 or their nuclear transport when compared with the empty vector control. While slight variations of Smad3 were observed in the cytoplasm, no significant differences were observed in the nucleus. The majority of core was observed in the cytoplasm and a minority in the nucleus, suggesting that, at least transiently, core can shuttle to the nucleus (Figure 3a) . Levels of core were not affected following treatment with TGF-b, in either compartment. These results were further confirmed by immunofluorescence labeling of endogenous Smad3 and core in Hep-G2-transfected cells. As shown in Figure 3b , shuttling of endogenous Smad3 was not affected in the presence of any core isolates, i.e, C1b, BNT or BT. Core was majority localized in the cytoplasm, but the results were also suggesting a minor fraction of core being HCV core protein inhibits the DNA-binding activity of the Smad3/4 complex Since core was found in small amount in the nucleus, it might modulate the DNA-binding activity of the Smad3/4 complex. Using a gel shift assay, we investigated the effect of GST-core fusion proteins on the capability of the Smad3/4 complex to bind a consensus Smad DNA-binding element (SBE primer). Nuclear extracts from TGF-b-stimulated Hep-G2 were preincubated with GST alone or with GST-IKK (as negative controls), or with various amounts (5, 15 or 30 ng) of GST-C1b, GST-BNT or GST-BT, and then incubated with 32 P end-labeled SBE primer and submitted to gel shift assay. Using this experimental procedure, a dose-dependent inhibition of the DNA-binding activity of the Smad3/4 complex to the SBE primer was observed in the presence of GST-BT (Figure 4c ). To a lesser extent, this inhibition was also observed with GST-BNT and GST-C1b. Comparison of the inhibitions observed, when using both 15 and 30 ng of each GST-core protein, clearly showed a more pronounced effect with GST-BT (5473.5 and 3470.5% of binding versus 8277 and 62713% for BNT and 8472.5 and 5673% for C1b) (Figure 4c ). These results suggest that different affinities between core and the Smad3/4 complex might be involved. In contrast, no effects were observed with either GST alone or with GST-IKK (Bonnet et al., 2000) ( Figure 4b ). To confirm the specificity of the band shift observed, a supershift assay was performed using an anti-Smad4 antibody (Figure 4a ). To further confirm the specificity of core inhibition, supershift of residual complex was performed after pre-incubation with 15 ng of GST-core C1b, BNT, BT and anti-Smad4 antibody ( Figure 4d ). In these experiments, supershifts of the Smad3/4-SBE complex, not inhibited by GSTcore, were observed, thus confirming that core compete for Smad3/4 complex binding. To confirm that Smad3 is present in the complex bound to the SBE probe, an anti-Smad3 antibody was used. Result did not show a supershift of the complex but an inhibition of the binding of Smad3/4 to its SBE probe, thus indirectly confirming the presence of Smad3 in the complex (Figure 4a ). Thus, core may block the Smad3/4-SBE complex formation by interacting with Smad3. Overall, these results clearly suggest that the BT mutant blocks the TGF-b pathway through an inhibition of the Smad3/4 complex binding to its consensus DNA element.
HCV core interacts directly with Smad3
We next investigated the molecular mechanism of this DNA-binding inhibition and tested whether core could directly interact with Smad3. First, the different GSTcore fusion proteins were used to pull down total cell extract of Hep-G2 cells stimulated with TGF-b. As shown in Figure 5a , 100, 200 or 500 ng of GST-C1b, GST-BNT or GST-BT were used, and Smad3 pull down was studied by immunoblotting. The results obtained have clearly shown a direct interaction between GSTcore and Smad3 (Figure 5a ). In these experiments, when 500 ng were used, binding was observed with all GSTC1b, GST-BNT and GST-BT with less Smad3 bound to GST-BNT or GST-C1b than to GST-BT. Using 200 ng of GST-BT, a stronger binding was observed with Smad3 (50%) when compared to GST-BNT (12%) or GST-C1b (7%), suggesting that different affinities might be involved. In contrast, GST control did not pull down Smad3. The specificity of the pull down with GST-BT was assessed by lowering the quantity of fusion protein down to 25 ng, and pull down of Smad3 was still observed (Figure 5b) , thus confirming the specific interaction of GST-BT with Smad3. To further address the specificity of the interaction of core with Smad3 and not another member of the Smad family, detection of Smad4 was performed by immunoblot in the same experiment. As shown in the lower part of Figure 5b , GST-BT did not pull down Smad4, even when higher To confirm our results in a more physiological context, whole liver tissue extract was used for GSTcore pull down. As shown in Figure 5a (right), a strong interaction between GST-core BT and endogenous Smad3 was observed. To a lesser extent, binding of Smad3 with GST-BNT and GST-C1b was also observed. Thus, Smad3 expressed in liver tissue interacts with GST-core, supporting their possible interaction in vivo.
In order to confirm the GST-core pull-down results, the complementary experiment using GST-Smad3 fusion protein was performed. GST-Smad3 proteins were incubated with whole-cell extracts from Hep-G2 cells transiently transfected with core-C1b, -BNT, -BT or HCV glycoprotein E2 (as negative control). Results have shown that GST-Smad3 was able to pull down all three different core proteins, regardless of their sequence, but not E2 (Figure 5c ). Differences in the quantity of core pulled down were correlated with the level of expression in each cell extract (data not shown). Smad4 was used as a positive control of GST-Smad3 pull down. The interaction Smad3-Smad4 was not disrupted in the presence of core, therefore, suggesting that core does not inhibit the Smad3/4 complex formation. To assess the affinity between Smad3 and the different core variants, lower quantity of GSTSmad3 was used, but it did not pull down any of the core proteins nor Smad4, suggesting technical limits to this assay.
To confirm our results in a more physiological context, extract from liver tumor of an HCV patient was used for GST-Smad3 pull down. As shown in Figure 5c , the interaction between GST-Smad3 and endogenous HCV core was observed. As expected core expression was low in tumor tissue, but sufficient to observe an interaction with GST-Smad3. Thus, this result further support an in vivo interaction between core and Smad3.
HCV core proteins interact with Smad3 in the polyprotein context
To further confirm the physiological interaction of core and Smad3 in the polyprotein context, we used a cell extract from FL/neo Replicon (Blight et al., 2000) . In this system, where all HCV proteins are synthesized, the pull down of core by GST-Smad3 was also observed. In contrast, GST-Smad3 protein did not pull down E2 (Figure 6e ). Thus, core and GST-Smad3 interact together when all HCV proteins are present.
To further confirm this interaction, co-immunoprecipitation experiments were performed in Hep-G2 cells cotransfected with the different core proteins C1b, BNT, BT and the 6-myc-tagged Smad3 plasmid. As no anticore antibody was available to us for efficient immunoprecipitation, co-immunoprecipitation was performed with an anti-myc antibody. Using this experimental procedure, a clear co-immunoprecipitation was observed between 6myc-Smad3 and the different core variants (Figure 5d ). The co-immunoprecipitation between Smad3 and Smad4 was also studied in the same experiment, and, as observed with the GST-Smad3 pull down, core had no effect on Smad3 and Smad4 interaction (Figure 5d ). Taken together, these results demonstrate a direct interaction between core and Smad3, which does not disrupt the Smad3/4 complex association. These results strongly suggest that binding of core with Smad3 is responsible for the inhibition of 
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Liver cell extract a b c d Figure 5 HCV core interacts directly with Smad3. (a) GST-core pull down assays were performed using GST (1 mg) or GST-BT, GST-BNT or GST-C1b (100, 200 or 500 ng) and 300 mg of Hep-G2 whole-cell extract or 400 ng of GST-BT, GST-BNT or GST-C1b with 300 mg of liver tissue extract (right panel). Pull down of Smad3 was analysed by immunoblot. (b) GST-core pull down assays using GST (1 mg) or GST-BT (25, 50, 100 ng) and 300 mg of Hep-G2 whole-cell extract. Pull down of Smad3 or -4 were analysed by immunoblot using the corresponding antibodies. Input corresponded to 10% of the whole-cell extract used for pull down. (c) GST-Smad3 pull down assays were performed using 1 mg of GST-Smad3 GST and 300 mg of whole-cell extracts from transiently transfected Hep-G2 with pRSV, pRSV-BNT (BNT), pRSV-BT (BT) or, right panel, with 300 mg of extract from liver tumor tissue of an HCV patient. Pull downs of Smad4 or core were analysed by immunoblot with the corresponding antibodies. Input corresponds to 10% of the whole extracts quantity used for pull down. (d) Co-immunoprecipitation was performed on whole-cell extracts (500 mg) from Hep-G2 co-transfected with a plasmid encoding 6-myc-tagged Smad3 and pRSV, pRSV-BNT or pRSV-BT. Anti-c-myc antibody was used for immunoprecipitation (IP) and anti-Smad4 or anti-core antibodies were used for Western blotting (WB). The control corresponded to an irrelevant antibody used for immunoprecipitation HCV tumor-derived core inhibit TGF-b signaling N Pavio et al the DNA binding of the Smad3/4 complex to its DNA target.
The central domain of core is involved in the interaction with the MH1 DNA-binding domain of Smad3
In order to map the interacting domains of core and Smad3, truncated forms of GST-BT or GST-Smad3 were used for pull down (Figure 6a and c). GST-BT was divided into three fragments, N-terminal (aa 1-58), central (aa 59-126) and C-terminal (aa 127-172) domains, and GST-Smad3 was either deleted from its MH1 domain (DMH1) or its MH2 domain (DMH2). GST-core pull down of Smad3 was performed on Hep-G2 cell extracts, treated or not with TGF-b. As shown in Figure 6b , Smad3 was pulled down by GST-BT independently of TGF-b induction. Among the different truncated GST-BTs, only forms containing the central domain (including aa 59 and 126) were able to pull down Smad3. Neither the N-terminal nor C-terminal domains alone were able to interact with Smad3. Thus, the central domain of tumor-derived core interact with Smad3. When using GST-BNT-truncated forms 1-126 and 59-126, we confirmed that core interacting domain with Smad3 expand from aa 59 to 126. We also consistently observed a lower interaction with truncated GST-BNT 1-126, suggesting that core 3D structure is important for Smad3 interaction. Using the different truncated GST-Smad3 fusion proteins, only the GST-Smad3 DMH-2 was capable of pulling down core in Hep-G2 cells transiently transfected with C1b, BNT or BT (Figure 6d ). As a negative control, HCV glycoprotein E2 was used. Detection of the interaction between Smad4 and the Smad3 MH2 domain was used as a positive control of mapping. The MH-1 domain of Smad3 is involved in its DNA-binding activity; thus, interaction of core with this domain very likely disrupts Smad3 interaction with its DNA sequence target. This finding is in line with the inhibition of Smad3/4 complex binding to DNA, as observed in gel shift assays.
To validate our observations in the presence all HCV proteins, mapping, using the different GST-Smad3-truncated forms, was repeated using FL/neo Replicon cell extracts. Detection of core, Smad4 and E2 was performed and, as shown in Figure 6e , the same results were obtained, that is, core interacted with the Smad3-MH1 domain, Smad4 with the Smad3-MH2 domain and E2 did not interact with Smad3. We therefore confirmed that the interaction of core with Smad3-MH1 occurred in the polyprotein context.
Discussion
Chronic HCV infection constitutes a high-risk factor for developing hepatocellular carcinoma after several years of cirrhosis. Carcinogenesis involves accumulation of several fatal mutations, and in the case of HCV, there is some evidence that both cellular and viral factors might be combined in HCV-induced HCC. Comparisons of (1 mg) were used to pull down whole-cell extracts (300 mg) of Hep-G2 transiently transfected with pRSV-C1b (C1b), pRSV-BNT (BNT), pRSV-BT (BT) or pCDNA-EF-E2 (E2). Pull downs of Smad4, core or E2 were analysed by immunoblot using the corresponding antibodies. Input corresponded to 10% of the whole extracts used. (e) The same pull down as in (d) was performed using whole-cell extract (300 mg) from FL/Neo Replicon cells. Smad4, core or E2 pull downs were analysed by immunoblot using the corresponding antibodies HCV replication in tumor and non-tumor tissues have shown a marked reduction of viral replication in tumor cells (Duvoux et al., 1999) , suggesting that low level of virus is produced in transformed cells. However, HCV viral RNA and proteins are present in tumor tissue, showing that the virus persists in tumor cells (Kobayashi et al., 1994) and may contribute to their transformed phenotype. It is well known that RNA viruses, such as HCV, are present as quasi-species in patients and that the viral population evolves over time. Studies of the genetic variability of HCV have shown that different viral variants are found in serum at various stages of the disease: chronic hepatitis, cirrhosis or HCC, thus confirming an evolution over time and progression of the disease. In the present study, we have investigated HCV core genetic variability in liver tumor or adjacent tissues and have addressed their effect on a cell-signaling pathway involved in cellular transformation. We have demonstrated the selection, within the liver of independent patients, of core mutants with a new biological property. We have identified HCV mutants derived from HCV-induced HCC able to inhibit the TGF-b signaling pathway. HCV core is a structural protein, which is well conserved among the six different genotypes, suggesting that its 3D structure is essential for viral assembly and does not allow many changes. Nevertheless, the analysis performed in the present study has shown that core sequences isolated in vivo, in tumor tissues or their nontumor counterparts, from four independent patients, exhibit several non-synonymous mutations. T and NT sequences did not exhibit any hot-spot mutations, but some of these were specific to tumor tissue when compared to databank. It is therefore difficult to identify HCV-1b isolates that were strongly associated with HCC on the basis of their primary structure. This suggests that in independent patients, even if quasispecies evolution is ruled by common environmental selective pressure (chronic inflammation and fibrosis, clonal cell expansion), it leads to several combinations of mutations that confer similar biological properties to core. The T and NT mutations were mostly located in the central and C-terminal domains of core, which have been suggested as being important for multimerization (Kunkel and Watowich, 2004) . Mutations in the multimerization domain of HCV core raise the possibility that these variants may be less efficient in viral assembly, thus providing more monomeric forms to interact with cellular proteins. Using T and NT isolates from these four patients, we investigated their effect on the TGF-b cell-signaling pathway and found that all of them were able to modulate TGF-b reporter activity with various degrees of inhibition. Thus, all four T mutants exhibited significant inhibition (0.027>P>0.001) of the TGF-b pathway when compared with a reference core sequence of genotype 1b (C1b). This finding strongly suggests that in tumor tissues, core variants inhibiting the TGF-b signaling pathway are selected and they may prevent the TGF-b antiproliferative effect.
Investigation of the molecular mechanisms involved led us to determine that overexpression of Smad3, one of the transcription factor activated upon TGF-b stimulation, fully restored core inhibition. Shuttling from the cytoplasm to the nucleus of the Smad3/4 complex was not affected, but in contrast, its DNAbinding activity was inhibited in the presence of GSTcore fusion proteins. This inhibition was dose and core sequence dependent (70% of inhibition with only 30 ng of GST-BT), suggesting a specific inhibition by tumorderived core variants. We have then demonstrated a direct interaction between core and Smad3. Using different amounts of GST-core in pull-down assays, our results have shown that core/Smad3 interaction is more pronounced with tumor-derived core than nontumor core or reference core. Indeed, when using 100 ng of GST-core fusion protein, only a specific binding with Smad3 was observed with the tumor-derived core variant BT, and not with its corresponding non-tumor sequence BNT or the core reference sequence C1b, suggesting that different affinities might be involved. The complementary GST pull down using GST-Smad3 was performed and the direct interaction between core and Samd3 was confirmed. However, pull down of core by GST-Smad3 was not specific to core tumor sequence. In this complementary experiment, high amounts of Smad3 (1 mg) were required for pull down of core as well as for positive control Smad4. Lowering the GSTSmad3 quantity led to a complete lost of interaction with all core variants and Smad4. It has not been possible to test directly in this assay whether different affinities were involved. However, several evidences such as results of TGF-b reporter assay, electrophoresis mobility shift assays (EMSA) and GST-core pull down suggest that different affinities between core variants and Smad3 might be involved. These different affinities would correlate with the specific inhibitory effect observed with tumor-derived isolates. Binding affinity studies, using native soluble core proteins would confirm the hypothesis that different affinities between various core sequences and Smad3 are responsible for this phenotype, but it has not yet been possible to generate such proteins and perform such studies.
To assess the biological relevance of our findings and confirm the interaction between core and Smad3 in the polyprotein context, we used cell extract from a cell line expressing full-length HCV polyprotein in a replication context (FL/neo Replicon) (Blight et al., 2000) . Using this system, we also found a direct interaction between core and GST-Smad3, thus confirming that HCV core binds to Smad3 when all HCV proteins are expressed.
To address the biological relevance of our finding in vivo, GST pull down were performed using endogenous Smad3 or core extracted from liver tissues. Similar results were obtained, for example, GST core could pull down Smad3 from liver tissue and GST-Smad3 could pull down HCV core in tumor tissue. We observed that core is expressed at low level in tumor tissue. However, tumor-derived core was still pulled down by GSTSmad3; this may be explained by a high affinity for Smad3, as compared with non-tumor core. Both of these results support the hypothesis that core and Smad3 interact together in vivo.
We then characterized the domains of tumor-derived core and Smad3 involved in this interaction. Using truncated forms of both GST-BT and GST-Smad3, we showed that the central domain of core (aa 59-126) and the MH1 domain of Smad3 were involved in this interaction. Along the same line, it is interesting to note that the BT mutant, which has a substitution at aa 118, also exhibited the strongest inhibitory effect on TGF-b signaling and, in our experimental system, the greatest affinity for Smad3. The central core domain is mostly hydrophilic, and the tryptophan-rich region 76-113 is largely solvent exposed, suggesting that it may interact with cellular proteins (Kunkel and Watowich, 2004) . Amino-acid substitutions in or near this domain may affect its secondary structure. Unfortunately, the 3D structure of core has not yet been resolved, and the putative motif of this region is not known. When using GST-BNT-truncated forms, we confirmed that the central domain (aa 59-126) of core is important for Smad3 binding. We also observed, consistently, that the GST-BNT 1-126 behaved differently from its tumor homolog GST-BT 1-126 and bound poorly Smad3. This result may suggest that core folding is different between these two isolates and might be crucial for Smad3 association. The absence of consensus sequences in tumor-derived core isolates led us to hypothesis that core 3D structure might be a key element in the interaction with Smad3. Mapping of the Smad3 domain involved in this interaction has shown that the MH1 domain of Smad3 interacts with HCV core. This fully agrees with the observation that interaction between core and Smad3 does not affect the Smad3/Smad4 association, which both interact through their MH2 domains. Furthermore, it is also consistent with inhibition of the DNA-binding activity of Smad3/4, since core interacts with the DNA-binding domain of Smad3. Consistent with our results, a very recent report by Cheng and collaborators has also described an inhibitory effect of HCV core on the TGF-b signaling pathway by a similar mechanism (Cheng et al., 2004) . However, they did not investigate whether or not the core and Smad3 interaction was dependent on core sequence. This issue is a key element for understanding and relevance of these findings in a pathophysiological context. In our present study, we have clearly shown that inhibition of TGF-b signaling by core is coresequence dependent and different affinities between HCV core variants and Smad3 are involved, suggesting that in tumor tissue, where less viral proteins are expressed, only core variants with the greatest affinity for Smad3 would exert an inhibitory effect.
The mechanism of inhibition identified in our study is similar to those identified for other viral oncoproteins, which inhibit the TGF-b pathway. For example, oncoprotein E7 of HPV, like HCV core, binds directly to MH1 domain Smad3 and blocks the DNA-binding activity of the Smad complex. However, the same authors found a loss of interaction between Smad3 and Smad4, which is not observed with HCV core (Lee et al., 2002b) . Similarly, adenoviral oncoprotein E1A inhibits the TGF-b pathway via both direct and indirect mechanisms. E1A interacts with the p300/CBP transcription coactivator and blocks the interaction of p300/ CBP with Smad3, resulting in a decrease in Smad complex transcriptional activity (Nishihara et al., 1999) . E1A also interacts directly with the MH2 domain of Smad3, contributing its the transcriptional inhibitory effect. In contrast, some other viral oncoproteins block the TGF-b pathway by indirect mechanisms. We have previously shown that the Tax protein of HTLV-1 activates the JNK pathway, leading to the formation of Smad3/c-Jun complexes that have lost their DNAbinding activity (Arnulf et al., 2002) . A recent report, however, suggests that the Tax protein could interact with Smad proteins (Lee et al., 2002a) . Finally, the LMP1 oncoprotein of EBV indirectly modulates the TGF-b signaling pathway by activating the p65/relA subunit of NF-kB through the activation of ERK1/2 (Fukuda et al., 2002) , and by inducing a depletion of p300/CBP. Thus, the ability to bind and inactivate Smad proteins appears to be a key function, shared not only by DNA viruses or retroviruses but also by some RNA viruses associated with oncogenesis. Furthermore, blocking the TGF-b signaling in oncogenesis is not restricted to virus-associated oncogenesis, it is frequently associated with various cancers. As an example, it is well established that the EV-1 oncogene, expressed in a subgroup of myeloid leukemia, inhibits Smad3 DNA binding through interaction with its MH1 domain (Kurokawa et al., 1998) .
Two recent studies have addressed the effect of core on TGF-b synthesis and fibrosis. One demonstrated an upregulation of TGF-b transcription by core (Taniguchi et al., 2004) , while the other showed that core and NS3 induce TGF-b synthesis in hepatic stellate cells and promote fibrogenesis (Bataller et al., 2004) . Induction of TGF-b might favor viral persistence by limiting the antiviral immune response. However, on the other hand, HCV replication and protein synthesis stimulate the immune system, triggering inflammation and additional fibrosis. Thus, our present study and those reported in the literature suggest that HCV protein may have biological properties that differ depending on the stage of liver disease and the selection of viral variants. In the case of HCV core, it is conceivable that firstly, it may contribute to fibrogenesis by increasing TGF-b synthesis, and then, after long-term of fibrosis and inflammation, core variants may contribute to clonal cell expansion and cellular transformation by inhibiting antiproliferative pathways.
In conclusion, we have provided substantial evidence of the biological importance of HCV quasi-species to HCC carcinogenesis. Until now, very few studies had been able to correlate HCV sequence variability with a gain in biological function. In a previous study carried out by our laboratory, it was shown that core tumor variants modulated the activity of interferon-induced RNA-activated protein kinase (PKR) and could influence cell survival (Delhem et al., 2001) . Another study on HCV NS3 has also shown that viral variants isolated in tumor tissue exhibit specific structural properties (Zemel et al., 2000; Ogata et al., 2003) . Here, we have demonstrated a novel specific biological property of HCV variants derived from tumor by showing their capacity to inhibit the TGF-b pathway. This activity may have major contribution in the development of HCV pathogenesis, by suppressing a key pathway in the control of cell growth and viability. Therefore, HCV, which is strongly associated with the development of HCC, shares a common cellular target with other oncoviruses and could be considered as a factor which contributes directly to cellular transformation and oncogenesis.
Materials and methods
Cell culture and plasmids
Human hepatoma Hep-G2 and Huh7.5 cell lines were maintained in Dulbecco's modified Eagle's medium with Glutamax (Gibco BRL, Life Technologies) supplemented with 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin (Gibco BRL, Life Technologies) and 2.5 mg/ml plasmocin (CAYLA, France). The FL/neo Replicon cell line (kindly provided by C Rice, Rockefeller University, New York City, USA) (Blight et al., 2000) was maintained in the same medium as Huh7.5, supplemented with 250 mg/ml of G418.
T and NT core sequences from patients P and T were amplified and cloned into the pDP18 plasmid (or pRSV) under the RSV promoter, as previously described by Delhem et al. (2001) . HCV core reference sequence C1b was cloned into the pRSV plasmid by amplification of the core-coding region of the infectious clone pCV-J4L6S (kindly provided by MMC LAI, USC, Los Angeles, USA). Wild-type Tax, 6-myc-tagged Smad3, CAGA 12 -luc reporter construct and expression vectors of glutathione S-transferase (GST)-Smad3 are described in Arnulf et al. (2002) . GST-cores and truncated forms were constructed as described by Yan et al. (unpublished yet) . Plasmid encoding GST-IKK was a kind gift from E Meurs (Pasteur Institute, Paris, France) (Bonnet et al., 2000) , and pCDNA-EF/E2 expression vector is described in Pavio et al. (2002) .
Transfection and reporter assays
Transfections were performed using Fugene reagent (Roche, France), in accordance with the manufacturer's instructions. The amount of total DNA transfected with the different combinations of expression vectors was kept constant in all experiments by the addition of pRSV plasmid. The pRSV b-galactosidase (b-gal) plasmid was used as an internal control of transfection efficiency. At 24 h after transfection, cells were stimulated with 7 ng/ml of recombinant human TGF-b (R&D Systems, Europe) in 0.2% SVF medium, for 18 h as described in Arnulf et al. (2002) . Cells were then lysed in a reporter lysis buffer (Promega, France) and luciferase and b-gal activities were measured using the Luciferase Assay System and b-Galactosidase Enzyme Assay System (Promega, France). Luciferase activity was normalized to that of b-gal. Experiments were performed in duplicate and Figure 1 shows the results of four independent experiments. Statistical analyses were performed using the StatView application.
GST-fusion proteins and pull-down assay
GST-fusion proteins were produced according to the protocol described by Bonnet et al. (2000) . For pull-down assays, 100, 200 or 500 ng of GST-core (C1b, BNT, BT), or 1 mg of truncated GST-BT, GST-Smad3, GST-Smad3DMH1, GSTSmad3DMH2, were incubated with 300 mg of whole-cell protein extracts in a final volume of 300 ml in HNGT buffer (20 mM HEPES (pH 7.9), 150 mM NaCl, 10% glycerol, 0.1% Triton X-100, 0.2 mM PMSF, 1 mM DTT). Following overnight incubation at 41C with gentle rotation, beads were washed three times with 1 ml cold HNGT buffer. Proteins were then eluted from the beads by boiling in a 2 Â SDS-PAGE sample buffer and then subject to SDS-PAGE and immunblotting. The GST-fusion proteins used in EMSA were eluted from Glutathione-sepharose 4B beads (Amersham Biosciences, Europe) using reduced glutathione 10 mM (Sigma) in Tris 50 mM. Glutathione was removed by dialysis with phosphate-buffered saline (PBS). Proteins were quantified by brilliant Coomassie blue staining and Bio-Rad protein assay (Bio-Rad, France).
Whole-cell, cytosolic and nuclear protein extracts
Protein extractions from transfected cells were performed 48 h after transfection, following overnight incubation with 0.2% SVF medium and 1 h of treatment with 7 ng/ml TGF-b. Cells were washed twice with PBS, harvested and lysed using the following buffer: 20 mM Tris (pH 7.8); 150 mM NaCl; 0.5 mM EDTA; 0.5 mM PMSF; 0.2% NP40 and one freeze and thaw cycle at À801C. For cytoplasmic and nuclear extracts, cells were washed twice in PBS, scraped and lysed using buffer A (20 mM HEPES (pH 7.9); 0.1 mM EDTA (pH 8); 0.1 mM EGTA; 10 mM KCl; 1 mM DTT; 1% NP40). After centrifugation for 5 min at 3000 r.p.m., the supernatant was kept as the cytoplasmic extract. The pellet was washed with buffer B (10 mM HEPES (pH 7.9); 100 mM NaCl; 0.1 mM EDTA (pH 8); 1 mM DTT, 25% glycerol) and then lysed with buffer C (10 mM HEPES (pH 7.9); 400 mM NaCl; 0.1 mM EDTA (pH 8); 1 mM DTT, 25% glycerol). Whole liver protein extracts were obtained using either liver biopsy from the tumor of patient with HCV or nontumor tissue from patient with liver metastasis. Liver tissues were washed in PBS and extraction was performed in RIPA buffer (50 mM Tris-HCl (pH 7.6); 150 mM NaCl; 1% Triton X-100; 1% desoxycholic acid; 0.1% SDS; antiproteasis cocktail) using an ultraturax apparatus. Protein quantities were determined using the Bio-Rad protein assay (Bio-Rad, France).
Antibodies for immunoblotting and immunoprecipitation
Monoclonal anti-core antibody was kindly provided by M Kohara (University of Tokyo, Japan). Antibodies directed against Smad3 (FL425), Smad4 (B8) and c-Myc (9E10) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal anti-E2 antibody was a kind gift from J Dubuisson (Pasteur Institute Lille, France).
Immunofluorescence
Hep-G2 cells were transfected with pRSV, pRSV-BT, -BNT or -C1b. At 48 h after transfection, cells were serum starved for 18 h and stimulated or not with 5 ng/ml of TGF-b during 45 min. After fixation in 4% PFA and permeabilization, cells were incubated for 1 h at room temperature with an anti-core antibody and then with a Texas-red conjugated goat antimouse antibody (Jackson Laboratories, France). The second labeling using the anti-Smad3 antibody was then performed with a secondary antibody Alexa-488-conjugated goat antirabbit antibody (Fluoprobe, France). Fluoresecence was then observed and analysed using a Nikkon Eclips E600 microscope and the imaging system CCD camera and analysis software ACT1.
Electrophoresis mobility shift assays
Smad binding element (SBE) oligonucleotides (Santa Cruz Biotechnologies, Santa Cruz, CA, USA) were end-labeled with [g-32 P]dATP (Amersham, France) using the T4 polynucleotide kinase (Promega, France). Reaction mix contained 10 mg of nuclear extract, various quantities of GST-fusion core (5, 15, 30 ng) and 2 ng of end-labeled SBE primer in 1 Â binding buffer (20 mM HEPES (pH 7.9); 30 mM KCl; 4 mM MgCl 2 ; 0.1 mM EDTA; 20% glycerol; 0.2% NP40; 4 mM spermidin; 3 mg poly-(dl-dC)). Binding reaction was performed at 371C for 20 min. Protein-DNA complex was resolved on 5% acrylamide gel. For supershift experiment, reaction mix was preincubated with anti-Smad4 antibody or anti-Smad3 antibody for 1 h at 41C. When supershifts were performed in the presence of GST-fusion proteins, nuclear extracts were first preincubated with GST-proteins for 1 h on ice and then for an additional 1 h with the anti-Smad4 antibody.
